Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Other Accumulated Expenses (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Other Accumulated Expenses data on record, last reported at $178419.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 31.47% year-over-year to $178419.0; the TTM value through Sep 2025 reached $178419.0, down 31.47%, while the annual FY2024 figure was $229319.0, 89.39% down from the prior year.
  • Other Accumulated Expenses reached $178419.0 in Q3 2025 per GANX's latest filing, down from $205849.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.5 million in Q2 2024 and bottomed at $178419.0 in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $1.7 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: soared 145.31% in 2022, then crashed 94.06% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.4 million in 2021, then surged by 50.2% to $2.1 million in 2022, then increased by 2.54% to $2.2 million in 2023, then tumbled by 89.39% to $229319.0 in 2024, then decreased by 22.2% to $178419.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $178419.0 in Q3 2025, $205849.0 in Q2 2025, and $222311.0 in Q1 2025.